Company intelligence / Profile preview

DrSignal BioTechnology

Ownership: Private
Employees: ~25
Development stage: Preclinical

Overview

DrSignal BioTechnology has developed an automated, AI-driven platform ("3A-GTP technology") that increases the efficiency and scalability of cell therapy manufacturing. The company transitioned from laboratory to commercial profitability in 2024 with new production lines launched. It is expanding internationally with a focus on overseas markets including Singapore, North America, and the Middle East. No specific clinical trial results are reported as it operates primarily as a CDMO rather than a direct therapeutic developer.

Therapeutic areas: OtherDermatology
Modalities: Cell therapyStem cell therapy
Industry: Contract Manufacturing Organization

Partnerships

Alliance with MiCell for green energy biotech initiatives using their core technologies

Beyond the preview

Go deeper on DrSignal BioTechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DrSignal BioTechnology.

Explore the full profile